Effects of surfactants on the properties of PLGA nanoparticles

Journal of Biomedical Materials Research - Part A

Volumn 100 A, Issue 8, 2012, Pages 1998-2005

  Menon, Jyothi U ^a,b   Kona, Soujanya ^a,b   Wadajkar, Aniket S ^a,b   Desai, Foram ^a,b   Vadla, Anupama ^a,b   Nguyen, Kytai T ^a,b  

^a University of Texas at Arlington   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

multidrug resistance; nanoprecipitation; PLGA nanoparticles; Pluronic; PVA

Indexed keywords

CELL CULTURE; CYTOLOGY; DISEASES; DRUG THERAPY; MUSCLE; NANOPARTICLES; SURFACE ACTIVE AGENTS;

HUMAN AORTIC SMOOTH MUSCLE CELLS; HUMAN DERMAL FIBROBLASTS; MULTIDRUG RESISTANCE; NANO PRECIPITATIONS; PLGA NANOPARTICLES; PLURONICS; POLY (VINYL ALCOHOL) (PVA); POLY(D ,L LACTIC CO GLYCOLIC ACID) (PLGA);

CELLS;

DOXORUBICIN; DRUG CARRIER; NANOPARTICLE; POLOXAMER; POLYGLACTIN; POLYVINYL ALCOHOL; SURFACTANT;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG RELEASE; DRUG RESISTANCE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MATERIAL COATING; PROSTATE CANCER; SKIN CELL; SMOOTH MUSCLE FIBER; SUSTAINED DRUG RELEASE;

EID: 85027949132     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34040     Document Type: Article

References (41)

1. Jain RA,. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21: 2475-2490.
2. Sahoo SK, Panyam J, Prabha S, Labhasetwar V,. Residual polyvinyl alcohol associated with poly (D, L -lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002; 82: 105-114.
3. Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ, Labrude P, Vigneron C,. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release 1998; 50: 31-40.
4. Wang YC, Wu YT, Huang HY, Yang CS,. Surfactant-free formulation of poly(lactic/glycolic) acid nanoparticles encapsulating functional polypeptide: A technical note. AAPS PharmSciTech 2009; 10: 1263-1267.
5. Monteiro-Riviere NA, Inman AO, Wang YY, Nemanich RJ,. Surfactant effects on carbon nanotube interactions with human keratinocytes. Nanomedicine 2005; 1: 293-299.
6. Batrakova E, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV,. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br J Cancer 2001; 85: 1987-1997.
7. Guo DD, Moon HS, Arote R, Seo JH, Quan JS, Choi YJ, Cho CS,. Enhanced anticancer effect of conjugated linoleic acid by conjugation with Pluronic F127 on MCF-7 breast cancer cells. Cancer Lett 2007; 254: 244-254.
8. Alakhova DY, Rapoport NY, Batrakova EV, Timoshin AA, Li S, Nicholls D, Alakhov VY, Kabanov AV,. Differential metabolic responses to Pluronic in MDR and non-MDR cells: A novel pathway for chemosensitization of drug resistant cancers. J Control Release 2010; 142: 89-100.
9. Batrakova EV, Kabanov AV,. Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008; 130: 98-106.
10. Lupertz R, Watjen W, Kahl R, Chovolou Y,. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology 2010; 271: 115-121.
11. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson M,. Phase I dose escalation and pharmacokinetic study of Pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 2004; 90: 2085-2091.
12. Santander-Ortega MJ, Jodar-Reyes AB, Csaba N, Bastos-Gonzalez D, Ortega-Vinuesa JL,. Colloidal stability of Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms. J Colloid Interface Sci 2006; 302: 522-529.
13. Bilati U, Allémann E, Doelker E,. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci 2005; 24: 67-75.
14. Shah B, Kona S, Gilbertson TA, Nguyen KT,. Effects of poly-(lactide-co-glycolide) nanoparticles on electrophysiological properties of enteroendocrine cells. J Nanosci Nanotechnol 2011; 11: 3533-3542.
15. Chastek T, Wadajkar A, Nguyen K, Hudson S, Chastek T,. Polyglycol-templated synthesis of poly(N-isopropyl acrylamide) microgels with improved biocompatibility. Colloid Polym Sci 2010; 288: 105-114.
16. Haas J, Ravi Kumar MN, Borchard G, Bakowsky U, Lehr CM,. Preparation and characterization of chitosan and trimethyl-chitosan-modified poly-(epsilon-caprolactone) nanoparticles as DNA carriers. AAPS PharmSciTech 2005; 6: E22-E30.
17. Kimura T, Okuno A, Miyazaki K, Furuzono T, Ohya Y, Ouchi T, Mutsuo S, Yoshizawa H, Kitamura Y, Fujisato T, Kishida A. Novel PVA-DNA nanoparticles prepared by ultra high pressure technology for gene delivery. Mater Sci Eng C 2004; 24: 797-801.
18. Kabanov AV, Batrakova EV, Alakhov VY,. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002; 82: 189-212.
19. Mainardes R, Evangelista RC,. PLGA nanoparticles containing praziquantel: Effect of formulation variables on size distribution. Int J Pharm 2005; 290: 137-144.
20. Koppolu B, Rahimi M, Nattama S, Wadajkar A, Nguyen KT,. Development of multiple-layer polymeric particles for targeted and controlled drug delivery. Nanomedicine 2010; 6: 355-361.
21. Tripathi A, Gupta R, Saraf SA,. PLGA nanoparticles of anti tubercular drug: Drug loading and release studies of a water in-soluble drug. Int J PharmTech Res 2010; 2: 2116-2123.
22. Song KC, Lee HS, Choung IY, Cho KI, Ahn Y, Choi EJ,. The effect of type of organic phase solvents on the particle size of poly(D, L -lactide-co- glycolide) nanoparticles. Colloids Surf A 2006; 276: 162-167.
23. Baoum A, Dhillon N, Buch S, Berkland C,. Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells. J Pharm Sci 2009; 99: 2413-2422.
24. Yoo HS, Lee KH, Oh JE, Park TG,. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release 2000; 68: 419-431.
25. Park J, Fong PM, Lu J, Russell KS, Booth CJ, Saltzman WM, Fahmy TM,. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine 2009; 5: 410-418.
26. Tewes F, Munnier E, Antoon B, Ngaboni Okassa L, Cohen-Jonathan S, Marchais H, Douziech-Eyrolles L, Souce M, Dubois P, Chourpa I,. Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm 2007; 66: 488-492.
27. Mukerjee A, Vishwanatha JK,. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009; 29: 3867-3875.
28. Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K,. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm 2007; 67: 1-8.
29. Zheng J, Chen C-T, Au J, Wientjes M,. Time-and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS J 2001; 3: 69-77.
30. Wang Z, Chui WK, Ho PC,. Design of a multifunctional PLGA nanoparticulate drug delivery system: Evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm Res 2009; 26: 1162-11671.
31. Huan M-L, Zhou S-Y, Teng Z-H, Zhang B-L, Liu X-Y, Wang J-P, Mei Q-B,. Conjugation with [α]-linolenic acid improves cancer cell uptake and cytotoxicity of doxorubicin. Bioorg Med Chem Lett 2009; 19: 2579-2584.
32. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ,. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009; 69: 3918-3926.
33. Harris TJ, Green JJ, Fung PW, Langer R, Anderson DG, Bhatia SN,. Tissue-specific gene delivery via nanoparticle coating. Biomaterials 2010; 31: 998-1006.
34. Zhang W, Shi Y, Chen Y, Ye J, Sha X, Fang X,. Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials 2011; 32: 2894-2906.
35. Li X, Li P, Zhang Y, Zhou Y, Chen X, Huang Y, Liu Y,. Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously. Pharm Res 2010; 27: 1498-1511.
36. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJ, Scheper RJ, Zaman GJ,. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994; 54: 4557-4563.
37. Kabanov AV, Batrakova EV, Alakhov VY,. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002; 54: 759-779.
38. Akan I, Akan S, Akca H, Savas B, Ozben T,. Multidrug resistance- associated protein 1 (MRP1) mediated vincristine resistance: Effects of N-acetylcysteine and buthionine sulfoximine. Cancer Cell Int 2005; 5: 22.
39. Chen J, Lu L, feng Y, Wang H, Dai L, li Y, Zhang P,. PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. Cancer Lett 2011; 300: 48-56.
40. Fedoruk MN, Giménez-Bonafé P, Guns ES, Mayer LD, Nelson CC,. P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate 2004; 59: 77-90.
41. Theyer G, Schirmbock M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G,. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 1993; 150 (5 Part 1): 1544-1547.